Loading…
Edesa Biotech, Inc. is projected to rise to $7.35 by 2027, a +5% move from its current price of $7.01. EDSA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.57 | $7.01 | $7.47 | -0.06% |
| Jul 14 | $6.40 | $7.00 | $7.66 | -0.12% |
| Jul 15 | $6.27 | $7.00 | $7.81 | -0.17% |
| Jul 16 | $6.16 | $6.99 | $7.94 | -0.23% |
| Jul 17 | $6.06 | $6.99 | $8.06 | -0.29% |
| Jul 18 | $5.98 | $6.99 | $8.16 | -0.35% |
| Jul 19 | $5.90 | $6.98 | $8.26 | -0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.90 | $6.98 | $8.26 | -0.41% |
| Week 2 | $5.48 | $6.95 | $8.82 | -0.81% |
| Week 3 | $5.17 | $6.92 | $9.27 | -1.22% |
| Week 4 | $4.92 | $6.90 | $9.66 | -1.62% |
| Week 5 | $4.71 | $6.87 | $10.01 | -2.02% |
| Week 6 | $4.53 | $6.84 | $10.33 | -2.42% |
| Week 7 | $4.36 | $6.81 | $10.64 | -2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edesa Biotech, Inc. (EDSA) is a clinical-stage biopharmaceutical company that engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
EDSA trades as a healthcare stock with a current price of $7.50 and a market capitalization of $72.2M, ranking 4292 by market cap. The stock sits in the public market with these base metrics, while the forecast paints a path of rising value over the coming years. In 2026, the expected average price is $7.50 with a neutral sentiment, suggesting limited near-term movement.
From 2027 onward, the outlook turns bullish, with steadily higher averages and meaningful upside through 2050.
A major floor 50.6% below — a decisive break under it would weaken the trend.
The nearest floor, 29.5% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 160.8% above — clearing it would confirm fresh momentum.
Key EDSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.17 | Sell | $7.19 | Sell |
| MA 10 | $7.51 | Sell | $7.28 | Sell |
| MA 20 | $7.14 | Sell | $7.40 | Sell |
| MA 50 | $9.62 | Sell | $7.85 | Sell |
| MA 100 | $7.53 | Sell | $7.17 | Sell |
| MA 200 | $4.67 | Buy | $5.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.07 | Neutral |
| Stoch RSI (14) | 6.08 | Buy |
| CCI (20) | -15.34 | Neutral |
| Williams %R (14) | -85.51 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | -8.25 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 14.49 | Buy |
| TRIX (15) | -0.73 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 24.68 | Buy |
| Momentum (10) | -0.46 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 6.97 | Buy |
| ADX (14) | 11.28 | Neutral |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is bullish overall. The RSI14 sits at 50, and the stock trades with a mix of momentum indicators in a constructive range. The SMA50 is $9.83 and the SMA200 is $4.55, indicating a recent crossover dynamic as the price hovers around mid-range levels.
Support is identified at $4.94 and resistance at $10.93, with a 30-day price range spanning $4.63 to $12.16.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.80 | $7.01 | $9.30 | 0% | Neutral | |
| $5.33 | $7.35 | $10.95 | +5% | Neutral | |
| $6.23 | $9.13 | $14.50 | +30% | Bullish | |
| $7.55 | $11.65 | $19.42 | +66% | Bullish | |
| $8.50 | $13.74 | $23.85 | +96% | Bullish | |
| $8.26 | $13.97 | $25.09 | +99% | Bullish | |
| $7.73 | $13.63 | $25.25 | +94% | Bullish | |
| $6.93 | $12.73 | $24.24 | +82% | Bullish | |
| $7.16 | $13.68 | $26.70 | +95% | Bullish | |
| $10.88 | $21.60 | $43.15 | +208% | Bullish | |
| $10.02 | $22.27 | $48.89 | +218% | Bullish | |
| $22.68 | $50.41 | $115.94 | +619% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.80 | $7.01 | $8.56 | +0.00% |
| August 2026 | $5.89 | $7.13 | $8.99 | +1.70% |
| September 2026 | $5.41 | $6.65 | $8.56 | -6.76% |
| October 2026 | $4.96 | $6.17 | $8.08 | -7.21% |
| November 2026 | $5.20 | $6.54 | $8.69 | +5.99% |
| December 2026 | $5.44 | $6.90 | $9.30 | +5.61% |
Click any year to see its month-by-month EDSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDSA to range from $0.80 to $9.30 through 2026. The $7.01 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EDSA price prediction for 2027 points to an average of $7.35 (low $5.33, high $10.95) — a potential gain of +5% on today's $7.01. A consolidation phase looks the most probable path here.
In 2028, EDSA is projected to trade between $6.23 and $14.50, averaging $9.13 — a potential gain of +30% from today's $7.01. That is up +24% on the projected 2027 average. Momentum favours further upside here.
Edesa Biotech, Inc.'s 2029 outlook centres on $11.65, within a $7.55 to $19.42 range. That is up +28% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, EDSA could reach as high as $23.85, with a base case around $13.74 and support toward $8.50 — roughly +96% from $7.01. Momentum favours further upside here.
Expect EDSA to range from $8.26 to $25.09 through 2031. The $13.97 average target implies a +99% move from current prices. That is up +2% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The EDSA price prediction for 2032 points to an average of $13.63 (low $7.73, high $25.25) — a potential gain of +94% on today's $7.01. Momentum favours further upside here.
In 2033, EDSA is projected to trade between $6.93 and $24.24, averaging $12.73 — a potential gain of +82% from today's $7.01. That is -7% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Edesa Biotech, Inc.'s 2034 outlook centres on $13.68, within a $7.16 to $26.70 range. That is up +7% on the projected 2033 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2035, EDSA could reach as high as $43.15, with a base case around $21.60 and support toward $10.88 — roughly +208% from $7.01. Buyers look set to stay in control over this stretch.
Expect EDSA to range from $10.02 to $48.89 through 2040. The $22.27 average target implies a +218% move from current prices. That is up +3% on the projected 2035 average. Momentum favours further upside here.
The EDSA price prediction for 2050 points to an average of $50.41 (low $22.68, high $115.94) — a potential gain of +619% on today's $7.01. Buyers look set to stay in control over this stretch.
Investing $1,000 in EDSA today (≈ 142.653352 EDSA) could be worth
$7,190.9
+$6,190.9 (+619%) by 2050 · US Dollar
Based on the average projected EDSA price of $50.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDSAwould be worth at today's price.
$1,000 invested in EDSA on Jul 10, 2025 (≈ 483.091803 EDSA) would be worth
$3,386.47
+$2,386.47 (+238.6%) today · 3.39× · US Dollar
Based on a EDSA entry price of $2.07 vs. today's $7.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.5 | $934.67 | -6.5% |
| 1 month ago | $5.21 | $1,345.49 | +34.5% |
| 3 months ago | $5.52 | $1,269.93 | +27.0% |
| 6 months ago | $1.48 | $4,736.49 | +373.6% |
| 1 year ago | $2.07 | $3,386.47 | +238.6% |
| All time (5.0y) ago | $35.91 | $195.21 | -80.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDSA forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $134.87M
The long-horizon forecast shows a clear bullish trajectory, with a rising average price through the 2020s and into 2050. The 2027 average is $9.63, followed by higher levels in 2028 ($14.96) and 2029 ($18.62), then $22.30 in 2030 and $24.42 in 2031, with a brief dip to $23.92 in 2032 before climbing again. By 2034 the average is $33.33 and by 2035 it is $49.53.
The multi-decade outlook then accelerates to a 2040 average of $63.38 and a 2050 average of $141.39, with max values reaching as high as $325.19 in 2050. Across these years, the forecast shows substantial upside in ROI, reaching 745 by 2040 and 1785.2 by 2050, while sentiment shifts to bullish in the later years. These figures illustrate a potential long-run appreciation, but they are estimates and not guarantees, with notable uncertainty inherent in early-stage biotechnology equities.
Tap a question to reveal the answer.
Avg $22.30; min $13.77; max $38.74; ROI: 197.4; sentiment: BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROI, while 2026 is neutral. Notably, ROI climbs to 745 by 2040 and to 1785.2 by 2050, indicating strong long-run upside, but these are estimates and involve risk.
The 2035 max is $98.98 and the 2040 max is $139.18, so the stock could surpass $100 by 2040 according to the forecast.
Current price is $7.50 and market cap is $72.2M; the rank is 4292.
The forecast shows a rise from 2026 onward, with 2027 avg $9.63, 2028 $14.96, 2029 $18.62, 2030 $22.30, 2031 $24.42, 2032 $23.92, 2033 $25.06, 2034 $33.33, 2035 $49.53, 2040 $63.38, and 2050 $141.39 as the average prices; ROI grows from 0 in 2026 to 745 in 2040 and 1785.2 in 2050, with sentiment turning bullish in the later years.
Edesa Biotech, Inc. Community Discussion
0Share your Edesa Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.